In an August 1 letter to the American public, the US Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) contend that unprecedented demand, potential overprescribing, and a lack of full production by manufacturers are the primary factors causing a shortage of stimulant drugs to treat attention deficit hyperactivity disorder (ADHD).
[
add
]
[
|
|
...
]